This database contains 429 studies, archived under the term: "USA"
Click here to filter this large number of results.
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M.,
Bell, K. L.,
Galasko, D.,
Galvin, J. E.,
Thomas, R. G.,
van Dyck, C. H.,
Aisen, P. S.
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Keren, R.,
Porsteinsson, A. P.,
van Dyck, C. H.,
Tariot, P. N.,
Gilman, S.,
Arnold, D.,
Abushakra, S.,
Hernandez, C.,
Crans, G.,
Liang, E.,
Quinn, G.,
Bairu, M.,
Pastrak, A.,
Cedarbaum, J. M.
Objective: This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid anti-aggregation agent) in mild to moderate Alzheimer disease (AD).; Methods: A total of 353 patients were randomized to ELND005 (250, 1,000, or 2,000 mg) or placebo twice daily for 78 weeks. Coprimary endpoints were the […]
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD
Vigen, Cheryl L. P.,
Mack, Wendy J.,
Keefe, Richard S. E.,
Sano, Mary,
Sultzer, David L.,
Stroup, T. Scott,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Tariot, Pierre N.,
Zheng, Ling,
Schneider, Lon S.
Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]
The effects of behavioral activation therapy with inpatient geriatric psychiatry patients
Snarski, Melissa,
Scogin, Forrest,
DiNapoli, Elizabeth,
Presnell, Andrew,
McAlpine, Jessie,
Marcinak, Jacquelyn
This study examined the effects of Behavioral Activation (BA) treatment on depressive symptoms and quality of life among older adult patients in a geriatric psychiatry facility. There were 50 participants with mild to moderate cognitive impairment, each being 65 years of age or older. A 2 (between)×3 (time of measurement) design was used in this […]
An MRI substudy of a donepezil clinical trial in mild cognitive impairment
Schuff, Norbert,
Suhy, Joyce,
Goldman, Robert,
Xu, Yikang,
Sun, Yijun,
Truran-Sacrey, Diana,
Murthy, Anita
A magnetic resonance imaging (MRI) study was conducted as part of an intervention study in subjects with amnestic mild cognitive impairment (aMCI) to assess donepezil’s treatment effect on brain atrophy. Adults with aMCI were randomly assigned to double-blind treatment with 10 mg/day donepezil hydrochloride or placebo for 48 weeks. Brain MRI scans were acquired at […]
Cognitive training changes hippocampal function in mild cognitive impairment: a pilot study
A randomized pilot experiment examined the neural substrates of response to cognitive training in participants with mild cognitive impairment (MCI). Participants performed exercises previously demonstrated to improve verbal memory and an active control group performed other computer activities. An auditory-verbal fMRI task was conducted before and after the two-month training program. Verbal memory scores improved […]
A phase II trial of huperzine A in mild to moderate Alzheimer disease
Rafii, M. S.,
Walsh, S.,
Little, J. T.,
Behan, K.,
Reynolds, B.,
Ward, C.,
Jin, S.,
Thomas, R.,
Aisen, P. S.
Objective: Huperzine A is a natural cholinesterase inhibitor derived from the Chinese herb Huperzia serrata that may compare favorably in symptomatic efficacy to cholinesterase inhibitors currently in use for Alzheimer disease (AD).; Methods: We assessed the safety, tolerability, and efficacy of huperzine A in mild to moderate AD in a multicenter trial in which 210 […]
Qualitative analysis of therapeutic light effects on global function in Alzheimer’s disease
The occurrence of Alzheimer’s disease (AD) is growing, with 68% of cases occurring in women. Declines in global function exacerbated by reversal of day-night patterns, disturbed sleep-wake rhythms, and excessive daytime sleepiness make managing AD difficult. In this study, the authors examined the effect and duration of effect of therapeutic light on sleep, rest-activity, and […]
Translation of a dementia caregiver support program in a health care system–REACH VA
Background: Based on the National Institute on Aging/National Institute of Nursing Research Resources for Enhancing Alzheimer’s Caregiver Health (REACH) randomized controlled trial (REACH II), REACH VA (Department of Veterans Affairs) was the first national clinical translation of a proven behavioral intervention for dementia caregivers, running from September 2007 through August 2009. This article describes the […]
Increasing walking and bright light exposure to improve sleep in community-dwelling persons with Alzheimer’s disease: results of a randomized, controlled trial
McCurry, Susan M.,
Pike, Kenneth C.,
Vitiello, Michael V.,
Logsdon, Rebecca G.,
Larson, Eric B.,
Teri, Linda
Objectives: To test the effects of walking, light exposure, and a combination intervention (walking, light, and sleep education) on the sleep of persons with Alzheimer’s disease (AD).; Design: Randomized, controlled trial with blinded assessors.; Setting: Independent community living.; Participants: One hundred thirty-two people with AD and their in-home caregivers.; Interventions: Participants were randomly assigned to […]